Purpose <p>Prior studies evaluating the genetic predisposition to chemotherapy induced peripheral neuropathy (CIPN) have been limited by small populations due to difficulty with real-world data extraction. This genome-wide association study (GWAS) evaluates the genetic differences between patients who developed CIPN against those unaffected, using an electronic health record (EHR) definition of CIPN.</p> Methods <p>This study included all patients who received chemotherapy associated with CIPN and had germline genetic data within the biobank at the Colorado Center for Personalized Medicine. CIPN was defined by a new neuropathic pain medication or an ICD-diagnosis of neuropathy after specified chemotherapy initiation. GWAS were stratified by (1) total population, (2) platinum chemotherapy, (3) taxane chemotherapy, and (4) vinca alkaloid chemotherapy. Genes previously associated with CIPN were analyzed within each GWAS.</p> Results <p>Nine hundred fifteen patients received chemotherapy associated with CIPN, with 528 patients (57%) developing CIPN. Median age at chemotherapy initiation was 60.5&#xa0;years; female sex (<i>n</i> = 517, 56.5%) and White or Caucasian race (<i>n</i> = 822, 89.8%) were most common. Among single nucleotide polymorphisms (SNPs) that reached suggestive levels of genome-wide significance (<i>p</i> &lt; 1 × 10⁻⁵), 60 SNPs occurred within 11 genes that may play a role in the development of or protection against CIPN, including <i>RCOR1</i>, <i>CLDN14</i>, <i>TRIM5</i>, and <i>TMC2</i>. No SNPs previously associated with CIPN achieved genome-wide significance in this population.</p> Conclusion <p>This pharmacogenomic study suggests several genomic loci that may modulate the development of CIPN. This EHR-definition may allow for increased sample sizes and improved statistical power in future genetic studies of CIPN.</p>